KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $835.9 million.

  • Emergent BioSolutions' Total Non-Current Liabilities fell 10.46% to $835.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $835.9 million, marking a year-over-year decrease of 10.46%. This contributed to the annual value of $867.8 million for FY2024, which is 24.21% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Total Non-Current Liabilities stood at $835.9 million, which was down 0.65% from $841.4 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Total Non-Current Liabilities ranged from a high of $1.7 billion in Q4 2022 and a low of $835.9 million during Q3 2025.
  • Over the past 3 years, Emergent BioSolutions' median Total Non-Current Liabilities value was $1.1 billion (recorded in 2024), while the average stood at $1.1 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 49.08% in 2023, then slumped by 35.48% in 2024.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Total Non-Current Liabilities stood at $1.3 billion in 2021, then spiked by 36.06% to $1.7 billion in 2022, then tumbled by 34.09% to $1.1 billion in 2023, then decreased by 24.21% to $867.8 million in 2024, then declined by 10.46% to $835.9 million in 2025.
  • Its last three reported values are $835.9 million in Q3 2025, $841.4 million for Q2 2025, and $838.0 million during Q1 2025.